Get In Touch

Global Fragment-based Drug Discovery Market to Reach US$1.2 bn by 2023, Asia Pacific to Witness Highest Growth

Transparency Market Research (TMR) has recently published a research study on the global fragment-based drug discovery market and estimated it to report a CAGR of 14.40% during the period from 2015 to 2023. The market is projected to increase from a value of US$0.4 bn in 2014 to a value of US$1.2 bn by the end of the forecast period.The research report, titled “Fragment-based Drug Discovery Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” states that the ease of usage and less consumption of time are the key properties that are increasing the popularity of fragment-based drug discovery.

Browse the full Fragment-based Drug Discovery Market (Service Component: Fragment screening and Fragment Optimization; End-user: Biopharmaceutical Companies, CROs and, Academic and Research Institutions) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 report at

In this research study, the global fragment-based drug discovery market has been evaluated on the basis of the service component and end user. Based on service component, the market is broadly segmented into fragment screening and fragment optimization. Of these, the fragment screening segment occupied the leading position in 2014.

The report further classifies this segment into biophysical techniques and non-biophysical techniques. The biophysical techniques segment is then categorized into differential scanning fluorimetry (DSF) assay (Thermal Shift), nuclear magnetic resonance (NMR) spectroscopy, x-ray crystallography, isothermal titration calorimetry (ITC), fluorescence polarization (FP), biolayer interferometry, surface plasmon resonance, capillary electrophoresis, mass spectrometry, and biochemical assays.

Biopharmaceutical companies, academic and research institutions, and CROs are the major end users of fragment-based drugs discovery services. In 2014, biopharmaceutical companies emerged as the biggest fragment-based drugs discovery services user and held a share of 46% in the overall market.

The report also analyzes the global market for fragment-based drug discoveries on the basis of its regional segmentation. According to the report, North America led the global market in 2014. The presence of pharmaceutical companies in a large number in the U.S. was the main factor behind the dominance of North America among all the regional markets for fragment-based drug discoveries including Latin America, Europe, Asia Pacific, and the Rest of the World.

The increasing research and development activities for fragment-based drug discoveries are projected to drive the North America fragment-based drug discovery market in the coming years, states the research report. However, analysts expect the fragment-based drug discovery market in Asia Pacific to exhibit the highest growth over the forecast period.

The rise in research and development activities for drug discovery in various emerging nations in Asia, together with the increasing demand for advanced medical and healthcare infrastructure, is likely to drive the growth of the Asia Pacific market for fragment-based drug discoveries, notes the study.

The global fragment-based drug discovery market is highly fragmented in nature, states the research report. Sygnature Discovery, Kinetic Discovery Ltd., Emerald BioStructures Inc., Evotec AG, Crown Bioscience Inc., Sprint Bioscience, Beactica AB, Astex Pharmaceuticals, Proteros Fragments GmbH, Charles River Laboratories International Inc., Structure Based Design Inc., and Alveus Pharmaceuticals Pvt. Ltd. are the major market participants mentioned in this study.

The global fragment-based drug discovery market is segmented into:

By Services Component

  • Fragment Screening
    • Biophysical Techniques
      • Nuclear Magnetic Resonance (NMR) Spectroscopy
      • Differential scanning Fluorimetry (DSF) Assay (Thermal Shift)
      • Fluorescence Polarization (FP)
      • Isothermal Titration Calorimetry (ITC)
      • X-ray Crystallography
      • Surface Plasmon Resonance
      • Biolayer Interferometry
      • Mass Spectrometry
      • Capillary Electrophoresis
      • Others (Biochemical Assays)
    • Non-biophysical Techniques
  • Fragment Optimization

Fragment-Based Drug Discovery Market, by End-user

  • Biopharmaceutical Companies
  • CROs
  • Academic and Research Institutions

Fragment-Based Drug Discovery Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific (APAC)
    • Australia
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Rest of the World (RoW)

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.


Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

7 of 10 large enterprizes view our ToC to take the right decision.

View Report ToC